JP6814522B2 - ジゴキシンの微粉化に関する非機械的プロセス - Google Patents
ジゴキシンの微粉化に関する非機械的プロセス Download PDFInfo
- Publication number
- JP6814522B2 JP6814522B2 JP2018503128A JP2018503128A JP6814522B2 JP 6814522 B2 JP6814522 B2 JP 6814522B2 JP 2018503128 A JP2018503128 A JP 2018503128A JP 2018503128 A JP2018503128 A JP 2018503128A JP 6814522 B2 JP6814522 B2 JP 6814522B2
- Authority
- JP
- Japan
- Prior art keywords
- digoxin
- methanol
- solution
- precipitate
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 title claims description 63
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 title claims description 62
- 229960005156 digoxin Drugs 0.000 title claims description 62
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 title claims description 62
- 238000010297 mechanical methods and process Methods 0.000 title description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 19
- 239000002244 precipitate Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000007857 degradation product Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003791 organic solvent mixture Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 240000001879 Digitalis lutea Species 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178009.5A EP3120839B1 (en) | 2015-07-23 | 2015-07-23 | Non-mechanical process for the micronization of digoxin |
| EP15178009.5 | 2015-07-23 | ||
| PCT/IB2016/001035 WO2017013485A1 (en) | 2015-07-23 | 2016-07-21 | Non-mechanical process for the micronization of digoxin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521073A JP2018521073A (ja) | 2018-08-02 |
| JP2018521073A5 JP2018521073A5 (enExample) | 2019-07-04 |
| JP6814522B2 true JP6814522B2 (ja) | 2021-01-20 |
Family
ID=54010825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503128A Expired - Fee Related JP6814522B2 (ja) | 2015-07-23 | 2016-07-21 | ジゴキシンの微粉化に関する非機械的プロセス |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180207099A1 (enExample) |
| EP (2) | EP3120839B1 (enExample) |
| JP (1) | JP6814522B2 (enExample) |
| KR (1) | KR20180032587A (enExample) |
| CN (1) | CN108024963A (enExample) |
| AU (1) | AU2016296162B2 (enExample) |
| ES (2) | ES2716681T3 (enExample) |
| HU (2) | HUE042420T2 (enExample) |
| MX (1) | MX365906B (enExample) |
| PL (2) | PL3120839T3 (enExample) |
| PT (2) | PT3120839T (enExample) |
| WO (1) | WO2017013485A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110632B (zh) * | 2018-10-31 | 2023-01-20 | 上海上药信谊药厂有限公司 | 一种地高辛气雾剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3643760A1 (de) * | 1986-12-20 | 1988-06-23 | Boehringer Mannheim Gmbh | Verfahren zur anreicherung und/oder isolierung von herzglykosiden unter verwendung unpolarer adsorberharze |
| WO2003007968A1 (en) | 2001-07-17 | 2003-01-30 | Sun Pharmaceutical Industries Ltd. | A cardiotonic composition |
| CN101390838A (zh) * | 2008-10-10 | 2009-03-25 | 北京工业大学 | 一种制备微粉化药物的方法 |
-
2015
- 2015-07-23 EP EP15178009.5A patent/EP3120839B1/en active Active
- 2015-07-23 ES ES15178009T patent/ES2716681T3/es active Active
- 2015-07-23 HU HUE15178009A patent/HUE042420T2/hu unknown
- 2015-07-23 PT PT15178009T patent/PT3120839T/pt unknown
- 2015-07-23 PL PL15178009T patent/PL3120839T3/pl unknown
-
2016
- 2016-07-21 AU AU2016296162A patent/AU2016296162B2/en not_active Ceased
- 2016-07-21 JP JP2018503128A patent/JP6814522B2/ja not_active Expired - Fee Related
- 2016-07-21 ES ES16754316T patent/ES2765675T3/es active Active
- 2016-07-21 HU HUE16754316A patent/HUE048065T2/hu unknown
- 2016-07-21 US US15/746,697 patent/US20180207099A1/en not_active Abandoned
- 2016-07-21 CN CN201680042406.3A patent/CN108024963A/zh active Pending
- 2016-07-21 KR KR1020187003325A patent/KR20180032587A/ko not_active Ceased
- 2016-07-21 PT PT167543164T patent/PT3324942T/pt unknown
- 2016-07-21 EP EP16754316.4A patent/EP3324942B1/en active Active
- 2016-07-21 WO PCT/IB2016/001035 patent/WO2017013485A1/en not_active Ceased
- 2016-07-21 MX MX2018001010A patent/MX365906B/es active IP Right Grant
- 2016-07-21 PL PL16754316T patent/PL3324942T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001010A (es) | 2018-05-17 |
| CN108024963A (zh) | 2018-05-11 |
| AU2016296162A1 (en) | 2018-02-01 |
| PL3120839T3 (pl) | 2019-08-30 |
| JP2018521073A (ja) | 2018-08-02 |
| HUE042420T2 (hu) | 2019-07-29 |
| PT3120839T (pt) | 2019-03-25 |
| BR112018001204A2 (pt) | 2018-09-11 |
| HUE048065T2 (hu) | 2020-05-28 |
| PL3324942T3 (pl) | 2020-05-18 |
| ES2765675T3 (es) | 2020-06-10 |
| MX365906B (es) | 2019-06-18 |
| US20180207099A1 (en) | 2018-07-26 |
| PT3324942T (pt) | 2020-01-17 |
| EP3120839B1 (en) | 2018-12-19 |
| EP3324942A1 (en) | 2018-05-30 |
| AU2016296162B2 (en) | 2021-03-18 |
| KR20180032587A (ko) | 2018-03-30 |
| WO2017013485A1 (en) | 2017-01-26 |
| EP3120839A1 (en) | 2017-01-25 |
| EP3324942B1 (en) | 2019-10-30 |
| ES2716681T3 (es) | 2019-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| JP2014169341A (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| JP2020079283A (ja) | 光安定性および溶出性に優れた医薬製剤 | |
| KR20160000762A (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 | |
| CN109988104B (zh) | 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途 | |
| JP2014114253A (ja) | 生薬を含有する鎮痛抗炎症用組成物 | |
| JP6814522B2 (ja) | ジゴキシンの微粉化に関する非機械的プロセス | |
| JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
| CN106620711B (zh) | 一种含有白藜芦醇的组合物及其制备方法 | |
| EP2359816A1 (en) | Aripiprazole formulations | |
| CN101367799A (zh) | 苦参碱丹参酚酸b复盐和苦参素丹参酚酸b复盐及其制备方法和用途 | |
| CN113057947A (zh) | 一种低ndma、小骨架盐酸二甲双胍缓释片及制备方法 | |
| EP1865926A2 (en) | Solid oral dosage form of valopicitabine (val-mcyd) and method of preparing it | |
| CN110478362A (zh) | 黄芩苷和黄芩素的降血氨作用及其医药用途 | |
| CN116019823B (zh) | 一种治疗儿童手足口病的药物组合物及其药物的应用 | |
| WO2019198661A1 (ja) | がん細胞の増殖抑制用組成物、抗がん用組成物、正常細胞のがん化抑制用組成物、がん発症抑制用組成物、及び、がん細胞死誘導用組成物 | |
| BR112018001204B1 (pt) | Processo não-mecânico para a micronização da digoxina | |
| WO2023283418A1 (en) | Prenylated chalcone and flavonoid compositions for use in treating cancer | |
| JP6910103B2 (ja) | 経口剤 | |
| CN104644576A (zh) | 一种替比夫定口腔崩解片及其制备方法 | |
| KR20140118410A (ko) | 저장 및 pH 안정성이 개선된 에페리손 의약 조성물 | |
| CN108938653A (zh) | 氧化型1,4-β-D-葡萄糖醛酸寡糖在制备治疗阿尔茨海默病的药物中的应用 | |
| KR20080035294A (ko) | 1,2-디[2-메톡시-4-(2-카르복실비닐)]페녹시에탄 화합물을유효성분으로 함유하는 파킨슨병 예방 및 치료용 약학적조성물 | |
| JPH03206044A (ja) | 抗レトロウイルス剤 | |
| HK1250652A1 (zh) | 辅酶q10的固体分散体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180322 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6814522 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |